CSL Limited’s board admitted recent financial performance was disappointing in a statement before the annual general meeting. Chairman Brian McNamee confirmed the search for a new Chief Executive Officer is well-advanced. The board committed to improving execution and market adaptation.
RBC Capital Markets upgraded CSL to outperform with a $213 price target. The broker expects core Behring plasma growth to offset weakness in the Seqirus and Vifor segments. This trajectory supports mid-single-digit EPS growth over the next three years.